Mithra Women’s Health, a BCI Pharma’s research partner, recognizes the high value of the partnership and considers as a top priority.

Follow the link to read Mithra’s press release

BCI Pharma is delighted to announce preclinical studies confirmed the broad therapeutic potential of its CSF1R inhibitors. These meaningful and compelling preclinical data come from a fruitful partnership with Mithra Women’s Health and cover medical areas for which unsatisfied therapeutic needs persist including cancer, endometriosis and inflammatory disorders.

Follow the link to read Mithra’s press release.